Beneficial effects of THSG on acetic acid-induced experimental colitis: Involvement of upregulation of PPAR-γ and inhibition of the Nf-Kb inflammatory pathway

Molecules

Volumn 16, Issue 10, 2011, Pages 8552-8568

  Zeng, Cheng ^a   Xiao, Jun Hua ^a   Chang, Mu Jun ^a   Wang, Jia Ling ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

2,3,5,4' tetrahydroxystilbene 2 O beta D glucoside; Colitis; NF B; PPAR

Indexed keywords

2,3,5,4' TETRAHYDROXYSTILBENE 2 O GLUCOSIDE; 2,3,5,4'-TETRAHYDROXYSTILBENE-2-O-GLUCOSIDE; ACETIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLUCOSIDE; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MALONALDEHYDE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STILBENE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED DISORDER; COLITIS; IMMUNOLOGY; MALE; METABOLISM; MOUSE;

ACETIC ACID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUGS, CHINESE HERBAL; GLUCOSIDES; INTERLEUKIN-6; MALE; MALONDIALDEHYDE; MESALAMINE; MICE; NF-KAPPA B; PPAR GAMMA; STILBENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054883778     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16108552     Document Type: Article

References (39)

1. Xavier, R. J.; Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448, 427-434. (Pubitemid 47123518)
2. Bosani, M.; Ardizzone, S.; Porro, G. B. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 2009, 3, 77-97.
3. De Vry, C. G.; Prasad, S.; Komuves, L.; Lorenzana, C.; Parham, C.; Le, T.; Adda, S.; Hoffman, J.; Kahoud, N.; Garlapati, R.; et al. Non-viral delivery of nuclear factor-kappab decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 2007, 56, 524-533. (Pubitemid 46580509)
4. Takedatsu, H.; Taylor, K. D.; Mei, L.; McGovern, D. P.; Landers, C. J.; Gonsky, R.; Cong, Y.; Vasiliauskas, E. A.; Ippoliti, A.; Elson, C. O.; et al. Linkage of crohn's disease-related serological phenotypes: Nfkb1 haplotypes are associated with anti-cbir1 and asca, and show reduced nf-kappab activation. Gut 2009, 58, 60-67.
5. Kelly, D.; Campbell, J. I.; King, T. P.; Grant, G.; Jansson, E. A.; Coutts, A. G.; Pettersson, S.; Conway, S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclearcytoplasmic shuttling of ppar-gamma and rela. Nat. Immunol. 2004, 5, 104-112. (Pubitemid 38081475)
6. Dubuquoy, L.; Rousseaux, C.; Thuru, X.; Peyrin-Biroulet, L.; Romano, O.; Chavatte, P.; Chamaillard, M.; Desreumaux, P. PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 2006, 55, 1341-1349. (Pubitemid 44277368)
7. Adachi, M.; Kurotani, R.; Morimura, K.; Shah, Y.; Sanford, M.; Madison, B. B.; Gumucio, D. L.; Marin, H. E.; Peters, J. M.; Young, H. A.; et al. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006, 55, 1104-1113. (Pubitemid 44085676)
8. Su, C. G.; Wen, X.; Bailey, S. T.; Jiang, W.; Rangwala, S. M.; Keilbaugh, S. A.; Flanigan, A.; Murthy, S.; Lazar, M. A.; Wu, G. D. A novel therapy for colitis utilizing ppar-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 1999, 104, 383-389. (Pubitemid 29534322)
9. Desreumaux, P.; Dubuquoy, L. Ppargamma agonists as a new class of effective treatment for ulcerative colitis. Inflamm. Bowel Dis. 2009, 15, 959-960.
10. Rousseaux, C.; Lefebvre, B.; Dubuquoy, L.; Lefebvre, P.; Romano, O.; Auwerx, J.; Metzger, D.; Wahli, W.; Desvergne, B.; Naccari, G. C.; et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J. Exp. Med. 2005, 201, 1205-1215. (Pubitemid 40629065)
11. Hontecillas, R.; Horne, W. T.; Climent, M.; Guri, A. J.; Evans, C.; Zhang, Y.; Sobral, B. W.; Bassaganya-Riera, J. Immunoregulatory mechanisms of macrophage ppar-gamma in mice with experimental inflammatory bowel disease. Mucosal Immunol. 2011, 4, 304-313.
12. Naito, Y.; Yoshikawa, T. [ppargamma as a new therapeutic target in inflammatory diseases]. Nippon Rinsho 2010, 68, 341-349.
13. Mohapatra, S. K.; Guri, A. J.; Climent, M.; Vives, C.; Carbo, A.; Horne, W. T.; Hontecillas, R.; Bassaganya-Riera, J. Immunoregulatory actions of epithelial cell ppar gamma at the colonic mucosa of mice with experimental inflammatory bowel disease. PLoS One 2010 5, e10215.
14. Liu, Q. L.; Xiao, J. H.; Ma, R.; Ban, Y.; Wang, J. L. Effect of 2, 3, 5, 4'-tetrahydroxystilbene-2-obeta-d-glucoside on lipoprotein oxidation and proliferation of coronary arterial smooth cells. J. Asian Nat. Prod. Res. 2007, 9, 689-697. (Pubitemid 350125720)
15. Zhang, W.; Wang, C. H.; Li, F.; Zhu, W. Z. 2, 3, 4', 5- tetrahydroxystilbene-2-o-beta-d-glucoside suppresses matrix metalloproteinase expression and inflammation in atherosclerotic rats. Clin. Exp. Pharmacol. Physiol. 2008, 35, 310-316. (Pubitemid 351257879)
16. Wang, R.; Tang, Y.; Feng, B.; Ye, C.; Fang, L.; Zhang, L.; Li, L. Changes in hippocampal synapses and learning-memory abilities in age-increasing rats and effects of tetrahydroxystilbene glucoside in aged rats. Neuroscience 2007, 149, 739-746. (Pubitemid 350130289)
17. Zhang, Y. Z.; Shen, J. F.; Xu, J. Y.; Xiao, J. H.; Wang, J. L. Inhibitory effects of 2, 3, 5, 4'-tetrahydroxystilbene-2-o-beta-d-glucoside on experimental inflammation and cyclooxygenase 2 activity. J. Asian Nat. Prod. Res. 2007, 9, 355-363.
18. Varilek, G. W.; Yang, F.; Lee, E. Y.; deVilliers, W. J.; Zhong, J.; Oz, H. S.; Westberry, K. F.; McClain, C. J. Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. J. Nutr. 2001, 131, 2034-2039. (Pubitemid 32661076)
19. Ukil, A.; Maity, S.; Das, P. K. Protection from experimental colitis by theaflavin-3, 3'-digallate correlates with inhibition of ikk and nf-kappab activation. Br. J. Pharmacol. 2006, 149, 121-131. (Pubitemid 44299075)
20. Ukil, A.; Maity, S.; Karmakar, S.; Datta, N.; Vedasiromoni, J. R.; Das, P. K. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br. J. Pharmacol. 2003, 139, 209-218. (Pubitemid 36760353)
21. Wang, X.; Zhao, L.; Han, T.; Chen, S.; Wang, J. Protective effects of 2, 3, 5, 4'-tetrahydroxystilbene-2-o-beta-d-glucoside, an active component of polygonum multiflorum thunb, on experimental colitis in mice. Eur. J. Pharmacol. 2008, 578, 339-348. (Pubitemid 350309579)
22. Wallace, J. L.; Braquet, P.; Ibbotson, G. C.; MacNaughton, W. K.; Cirino, G. Assessment of the role of platelet-activating factor in an animal model of inflammatory bowel disease. J. Lipid Mediat. 1989, 1, 13-23. (Pubitemid 19132696)
23. Sanchez-Munoz, F.; Dominguez-Lopez, A.; Yamamoto-Furusho, J. K. Role of cytokines in inflammatory bowel disease. World J. Gastroenterol. 2008, 14, 4280-4288.
24. Suzuki, A.; Hanada, T.; Mitsuyama, K.; Yoshida, T.; Kamizono, S.; Hoshino, T.; Kubo, M.; Yamashita, A.; Okabe, M.; Takeda, K.; et al. Cis3/socs3/ssi3 plays a negative regulatory role in stat3 activation and intestinal inflammation. J. Exp. Med. 2001, 193, 471-481. (Pubitemid 32524478)
25. Rogler, G.; Andus, T. Cytokines in inflammatory bowel disease. World J. Surg. 1998, 22, 382-389. (Pubitemid 28113526)
26. Tsatsanis, C.; Androulidaki, A.; Venihaki, M.; Margioris, A. N. Signalling networks regulating cyclooxygenase-2. Int. J. Biochem. Cell Biol. 2006, 38, 1654-1661. (Pubitemid 43947653)
27. Khoshakhlagh, P.; Bahrololoumi-Shapourabadi, M.; Mohammadirad, A.; Ashtaral-Nakhai, L.; Minaie, B.; Abdollahi, M. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol. Mech. Methods 2007, 17, 281-288. (Pubitemid 46956946)
28. Carroll, I. M.; Andrus, J. M.; Bruno-Barcena, J. M.; Klaenhammer, T. R.; Hassan, H. M.; Threadgill, D. S. Anti-inflammatory properties of lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293, G729-738. (Pubitemid 47605922)
29. Haddad, J. J. Amiloride and the regulation of nf-kappab: An unsung crosstalk and missing link between fluid dynamics and oxidative stress-related inflammation-controversy or pseudocontroversy? Biochem. Biophys. Res. Commun. 2005, 327, 373-381. (Pubitemid 40040487)
30. Shen, H. M.; Pervaiz, S. Tnf receptor superfamily-induced cell death: Redox-dependent execution. FASEB J. 2006, 20, 1589-1598. (Pubitemid 44943796)
31. Del Rio, D.; Stewart, A. J.; Pellegrini, N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. 2005, 15, 316-328. (Pubitemid 41190990)
32. Wahli, W. A gut feeling of the pxr, ppar and nf-kappab connection. J. Intern. Med. 2008, 263, 613-619. (Pubitemid 351678588)
33. Bensinger, S. J.; Tontonoz, P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454, 470-477.
34. Aoyagi, Y.; Nagata, S.; Kudo, T.; Fujii, T.; Wada, M.; Chiba, Y.; Ohtsuka, Y.; Yamashiro, Y.; Shimizu, T.; Ohkusa, T. Peroxisome proliferator-activated receptor gamma 2 mutation may cause a subset of ulcerative colitis. Pediatr. Int. 2010, 52, 729-734.
35. Yamamoto-Furusho, J. K.; Penaloza-Coronel, A.; Sanchez-Munoz, F.; Barreto-Zuniga, R.; Dominguez-Lopez, A. Peroxisome proliferator-activated receptor-gamma (ppar-gamma) expression is downregulated in patients with active ulcerative colitis. Inflamm. Bowel Dis. 2011, 17, 680-681.
36. Sanchez-Hidalgo, M.; Martin, A. R.; Villegas, I.; de la Lastra, C. A. Rosiglitazone, a ppargamma ligand, modulates signal transduction pathways during the development of acute tnbs-induced colitis in rats. Eur. J. Pharmacol. 2007, 562, 247-258. (Pubitemid 46560498)
37. Nissen, S. E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356, 2457-2471. (Pubitemid 46919772)
38. Zhang, S. H.; Wang, W. Q.; Wang, J. L. Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo. Acta Pharmacol. Sin. 2009, 30, 1479-1487.
39. Zhang, J. D.; Jiang, Y. Y.; Cao, Y. B.; Chen, W. S.; Xu, Z. Toxicological study of stilbene glycoside (In Chinese). Chin. Pharmacol. 2004, 4, 37.